Authors: Geczi, L Gomez, F Horvath, Z Bak, M Kisbenedek, L Bodrogi, I

Citation: L. Geczi et al., Three-year results of the first educational and early detection program for testicular cancer in Hungary, ONCOL-BASEL, 60(3), 2001, pp. 228-234

Authors: von der Maase, H Hansen, SW Roberts, JT Dogliotti, L Oliver, T Moore, MJ Bodrogi, I Albers, P Knuth, A Lippert, CM Kerbrat, P Rovira, PS Wersall, P Cleall, SP Roychowdhury, DF Tomlin, I Visseren-Grul, CM Conte, PF

Citation: H. Von Der Maase et al., Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study, J CL ONCOL, 18(17), 2000, pp. 3068-3077

Authors: Eid, H Liu, MF Institoris, E Bodrogi, I Bak, M

Citation: H. Eid et al., MRP expression of testicular cancers and its clinical relevance, ANTICANC R, 20(5C), 2000, pp. 4019-4022

Authors: Chan, S Friedrichs, K Noel, D Pinter, T Van Belle, S Vorobiof, D Duarte, R Gil, MG Bodrogi, I Murray, E Yelle, L von Minckwitz, G Korec, S Simmonds, P Buzzi, F Mancha, RG Richardson, G Walpole, E Ronzoni, M Murawsky, M Alakl, M Riva, A Crown, J

Citation: S. Chan et al., Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer, J CL ONCOL, 17(8), 1999, pp. 2341-2354

Authors: Eid, H Institoris, E Geczi, L Bodrogi, I Bak, M

Citation: H. Eid et al., mdm-2 expression in human testicular germ-cell tumors and its clinical value, ANTICANC R, 19(4C), 1999, pp. 3485-3490